Moreno-Ramírez, DBoada, AFerrándiz, LSamaniego, ECarretero, GNagore, ERedondo, POrtiz-Romero, PMalvehy, JBotella-Estrada, Rmiembros del Grupo Español de Dermato-Oncología y Cirugía. Academia Española de Dermatología y Venereología2025-01-072025-01-072018-04-09https://hdl.handle.net/10668/24821Recent publication of the results of clinical trials in which lymph node dissection was not associated with any survival benefit in patients with sentinel node metastasis makes it necessary to reconsider the treatment of patients with melanoma. This article provides an update on the available evidence on the diverse factors (routes of metastatic spread, predictors, adjuvant therapy, etc.) that must be considered when treating patients with sentinel node-positive melanoma. The authors propose a decision-making algorithm for use in this clinical setting. The current evidence no longer supports lymph node dissection in patients with low-risk sentinel node metastasis (sentinel node tumor load ≤1mm).enAdjuvant therapyBiopsia selectiva del ganglio centinelaDisección ganglionarLymph node dissectionMelanomaSentinel lymph node biopsyTratamiento adyuvanteAlgorithmsClinical Decision-MakingEvidence-Based MedicineHumansLymph Node ExcisionLymphatic MetastasisMelanomaPractice Guidelines as TopicSentinel Lymph NodeSkin Neoplasmsresearch article2965022110.1016/j.ad.2018.02.0082173-5778